Text Size

Sub Total : $0.00
Place your mouse over each cart item to see full description.

Chemical Name: Calcitriol

Please select Dosage and Quantity
  Product Manufacturer Country Dosage Quantity Price($USD)    
Rocaltrol  Roche Pharmaceuticals Canada 0.25 mcg 100 $151.99
Rocaltrol  Roche Pharmaceuticals Canada 0.5 mcg 100 $201.99
Calcitriol  Generic Canada 0.25 mcg 100 $101.99
Calcitriol  Generic New Zealand 0.5 mcg 100 $101.99
Calcitriol 10 x 1ml Generic Canada 1 mcg/ml 1 $271.99

Rocaltrol Information:

Rocaltrol is indicated for the correction of the abnormalities of calcium and phosphate metabolism in patients with renal osteodystrophy. Rocaltrol is also indicated for the treatment of established post-menopausal osteoporosis. The dose of Rocaltrol should be carefully adjusted for each patient according to the biological response so as to avoid hypercalcaemia.
Rocaltrol should not be given to patients with hypercalcaemia or evidence of metastatic calcification. The use of Rocaltrol in patients with known hypersensitivity to calcitriol (or drugs of the same class) and any of the constituent excipients is contra-indicated. Rocaltrol is contra-indicated if there is evidence of vitamin D toxicity.
The effectiveness of treatment depends in part on an adequate daily intake of calcium, which should be augmented by dietary changes or supplements if necessary. The capsules should be swallowed with a little water. Oral intermittent (pulse) therapy with Rocaltrol two or three times weekly has been shown to be effective in patients with osteodystrophy refractory to continuous therapy. Adults: Renal Osteodystrophy- The initial daily dose is 0.25mcg of Rocaltrol. In patients with normal or only slightly reduced calcium levels, doses of 0.25mcg every other day are sufficient. If no satisfactory response in the biochemical parameters and clinical manifestations of the disease is observed within 2 - 4 weeks, the dosage may be increased by 0.25mcg daily at 2 - 4 week intervals. During this period, serum calcium levels should be determined at least twice weekly. Should the serum calcium levels rise to 1mg/100ml (250µmol/l) above normal (9 to 11mg/100ml or 2250 - 2750µmol/l), or serum creatinine rises to> 120µmol/l, treatment with Rocaltrol should be stopped immediately until normocalcaemia ensues. Most patients respond to between 0.5mcg and 1.0mcg daily. Higher doses may be necessary if barbiturates or anticonvulsant drugs are administered simultaneously. Post-menopausal Osteoporosis- The recommended dose of Rocaltrol is 0.25mcg twice daily. Serum calcium and creatinine levels should be determined at 4 weeks, 3 and 6 months and at 6 monthly intervals thereafter. Elderly- Clinical experience with Rocaltrol in elderly patients indicates that the dosage recommended for use in younger adults may be given without apparent ill-consequence.

MediSave.ca supplies only genuine Rocaltrol from Canada shipped using the Canadian packaging. This Rocaltrol is manufactured by Genetech Inc. (a member of Roche Group), the worldwide manufacturer of Rocaltrol. This offer is neither endorsed nor authorized by Genetech Inc. (the United States and Canadian distributor of Rocaltrol). MediSave.ca has no affiliation whatsoever with Genetech Inc. Children- Dosage in children has not been established. Rocaltrol capsules are for oral administration only.

Rocaltrol Side Effects:

The number of adverse effects reported from clinical use of Rocaltrol over a period of 15 years in all indications is very low with each individual effect, including hypercalcaemia, occurring rarely. Hypercalcaemia and hypercalcuria are the major side effects of Rocaltrol and indicate excessive dosage. Patients with tertiary hyperparathyroidism, renal failure, or on regular haemodialysis are particularly prone to develop hypercalcaemia. The clinical features of hypercalcaemia include anorexia, constipation, nausea, vomiting, headache, weakness, apathy and somnolence. More severe manifestations may include thirst, dehydration, polyuria, nocturia, abdominal pain, paralytic ileus and cardiac arrhythmias. Rarely, overt psychosis and metastatic calcification may occur. The relatively short biological half-life of Rocaltrol permits rapid elimination of the compound when treatment is stopped and hypercalcaemia will recede within 2 - 7 days. This rate of reversal of biological effects is more rapid than when other vitamin D derivatives are used. In patients with normal renal function, chronic hypercalcaemia may be associated with an increase in serum creatinine. Mild, non-progressive and reversible elevations in levels of liver enzymes (SGOT, SGPT) have been noted in a few patients treated with Rocaltrol, but no pathological changes in the liver have been reported. Hypersensitivity reactions may occur in susceptible individuals.

The generic alternative is not manufactured by the company that makes the brand product.

All prices are in US dollars.

The content on this page has been supplied to MediSave.ca by an independent third party contracted to provide information for our website. MediSave.ca relies on these third parties to create and maintain this information and cannot guarantee the medical efficacy, accuracy or reliability of the information that has been provided to us. If you require any advice or information about the drugs on this page, a medical condition or treatment advice, you should always speak to a health professional. Please note that not all products, including any referenced in this page, are shipped by our affiliated Canadian Pharmacy. We affiliate with other dispensaries that ship product to our customers from the following jurisdictions: Canada, Singapore, New Zealand, Turkey, Mauritius, India, and United Kingdom. The items in your order maybe shipped from any of the above jurisdictions. The products are sourced from various countries as well as those listed above. Rest assured, we only affiliate with our authorized dispensaries that procure product through reliable sources.

Back to Main Drug Information Page